All In Biotech

Drug Trial Radar · NCT02097485

Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

A Randomised, Double-Blind, Vehicle-Controlled Study of Ovicidal Efficacy and Safety of Abametapir 0.74% Administered for the Treatment of Head Lice Infestation

Last checked: Nov 20, 2026Latest source record: May 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

May 2014

Primary completion

Sep 2014

Study completion Oct 2014

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to evaluate ovicidal efficacy of a single application of abametapir lotion 0.74% w/w intended for the treatment of head lice.

Conditions

  • Head Lice Infestation

Interventions

  • Abametapir Lotion 0.74% w/wDrug

    200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.

  • Vehicle LotionDrug

    control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Hatched Eggs Pre Treatment Relative to Post TreatmentTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Head Lice Treatment Centre

    Ringwood East, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.